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In previous studies cn the immunization of human beings with type-specific 
polysaccharides of pneumococcus (1, 2) the serological evidence of an immune 
response has been based exclusively on relative methods such as mouse pro- 
tection or  the  agglutinin  or precipitin  titers  of sera  of the vaccinated indi- 
viduals, owing to the lack of any method suitable for estimating the very small 
quantities of antibody ordinarily present in human sera.  Recently, however, 
modifications have been introduced by which quantitative absolute  methods 
for the estimation of antibody nitrogen (3, 4) were made applicable to amounts 
as small as a few micrograms (5, 6).  Essential changes were the use of a more 
sensitive method for measuring antibody protein, allowance of sufficient time 
for small quantities of specific precipitates to separate from the viscous serum 
medium, and  use of relatively much  serum  (about 4  ml. per determination) 
when  necessary.  The  present  paper  deals  with  data  obtained  by  the  new 
method with the sera of (a) a  group of medical students injected with Type I 
and  Type II pneumococci, (b)  three groups  injected with  small amounts  of 
Type I  and  Type II specific polysaccharides, and  (c)  a  group injected with 
Types  I,  II,  and  V  specific polysaccharides.  A  comparison  of  the  results 
with the mouse-protective titers of representative sera is given in the following 
paper  (7). 
As the study of the initial prevaccination sera progressed  it was found that few 
contained more than traces, at most, of antibodies to the type-specific polysaccharides 
of Types I, II, III, IV, and V pneumococci.  When the sera were tested with Type 
VII  polysaccharide,  however,  most  of  them  reacted,  many  quite  strongly.  On 
closer scrutiny it developed that the sample  of Type VII polysaccharide used  con- 
rained roughly one-third of its weight of the C substance of pneumococcus  (8) and 
that  the greater portion of the precipitates obtained with  the crude material was 
due to the reaction of the C substance with anti-C present in almost all of the sera. 
* This  investigation was  supported in  part  through  the  Commission on Pneumonia, 
Board for the Investigation and  Control of Influenza and Other Epidemic Diseases in the 
Army, Preventive Medicine Service, Office  of The Surgeon General, United States Army, 
and in part under the auspices of the Harkness Research Fund of the Presbyterian Hospital, 
New York. 
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Owing to the widespread occurrence of antibodies reactive with C substance in normal 
sera  it  became  necessary  to  remove  these  prior  to  estimation  of  the  type-specific 
response due to vaccination, since almost all samples of type-specific polysaccharides 
contain C substance as an impurity and analytical results would otherwise tend tobe 
too high.  This must be borne in mind in any evaluation of the earlier portions of the 
new data, which were obtained before the necessity of a  preliminary absorptionwith 
C  substance  became  evident. 
Materials, Subjects, and Methods 
Types 1 and  II Pneumococd.--Formalinized  young cultures in broth were centrifuged, 
washed with saline and twice with acetone (9), and dried in ~uo.  The bacteria of each type 
were resuspended  as evenly as possible in sterile saline and decanted from large particles. 
The cell count was about 100 X  10 ~ per ml.  After removal of aliquot portions for estima- 
tion of the polysaccharide content of the vaccines, 1 per cent by volume of 1 per cent merthio- 
latO was added.  2.0 ml. aliquot portions of each vaccine were incubated at 37°C. in closed 
25 ml. flasks with 3 ml. of saline and 2.6 ml. of N NaOH.  After 3 days the clear solutions 
were neutralized with N HC1 and made up to 25 ml. with saline and water so that the final 
solutions would be approximately isotonic.  Aliquot portions of each were added to meas- 
ured  quantities of homologous antipneumococcus  horse  serum which had  been  calibrated 
(10) with similarly treated specific polysaccharide, the amounts chosen being such that anti- 
body remained in excess.  From the quantity of nitrogen precipitated the amount of specific 
polysaccharide in the aliquot could be read from the calibration curve of the serum  (10), 
and the quantity per milliliter of vaccine calculated.  In this way it was found that 10 bil- 
lion of the Type I  pneumococci, the dose of vaccine given to group  1, contained 0.03  rag. 
S 12 while 10 billion of the Type II pneumococci contained 0.04 rag. S II.  2 
Specific Polysaccharides of Pneumococcus.--The  type-specific polysaccharides  used were 
prepared essentially as already described  (11),  after preliminary ultrafiltration (12),  except 
those used in group 5 which were isolated by the phenol method (13).  Samples of C  sub- 
stance (8) were derived either from pneumococcus types other than those used for immuniza- 
tion or from pneumococci in the R  (Dawson S) phase.  Since blood group A substance origi- 
nating in the culture media (14) might tend to concentrate in the relatively crude C fraction 
two samples were tested for A activity by the method of inhibition of hemagglutination, a 
One sample was roughly one-tenth as active as a purified A substance, the other was entirely 
inactive.  Since the amounts of C substance used for absorption were far below the order of 
magnitude  required for the precipitation of antibody  by A  substance  (15),  and since the 
amounts of anti-C found appeared unrelated to the blood group of the subject, it is probable 
that the anti-C values given in the tables are rarely augmented by precipitation of anti-A. 
Subjeas.--Medical student volunteers, with no previous history of allergy, were studied. 
The writers are greatly indebted to these men and women, who submitted cheerfully to the 
injections and to the inconveniences of repeated bleedings despite the rigors of an accelerated 
medical program.  Hearty  thanks  are also due  to  the many  members of the staff of the 
Presbyterian Hospital who assisted with the injections and bleedings. 
Many of the injections were followed by local reactions, of which few were severe.  Several 
general reactions were also encountered. 
Group  1,  13 subjects: Received two intracutaneous injections, 3 days apart,  totalling 10 
billion each Type I  and Type II pneumococci containing 0.03  rag. S 12 and 0.04 rag.  S II  2. 
1 Manufactured by Eli Lilly & Company, Indianapolis, Indiana. 
t S I  =  specific polysaccharide of Type I  pneumococcus, S II  =  specific polysaccharide 
of Type II pneumococcus, etc. 
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Group 2, 13 subjects: Received two intracutaneous injections, 5 days apart, of the washed 
copper precipitate from a solution of S I and S II.  It is doubtful whether the entire amounts 
intended, 0.03 mg.  S I and 0.04 rag. S II for comparison in particulate form with the vac- 
cine, were actually injected, as the gummy material tended to stick in the syringes. 
Group 3, 11 subjects: Received two intracutaneous injections, 6  days apart, of polysac- 
chsride sol,ion, totalling 0.05 mg. each of S I  and S II. 
Group 4, 9  subjects:  Were treated like those of group 3, save that the polysaccharides 
were injected subcutaneously in two doses, 8 days apart. 
Group 5, 20 subjects: Received 0.06 mg. each of S I, II, and V, injected subcutaneously 
in two doses, 3 days apart. 
Anal),s~s of Sera.--The first analyses of group 1 and group 2 sera were made with the aid 
of the micro-Kjeldahl method (3, 4), but use of this method was discontinued because the 
quantities of antibody nitrogen found were usually little greater than the analytical error 
involved.  Most of the analyses were accordingly carried out by application of a  modified 
Folin-Ciocalteau method (5, 6). 
All analyses were run under conditions favoring sterility, owing to the long period required, 
but 1 per cent by volume of 1 per cent merthiolate  I was added to the materials as an ad- 
ditional precaution.  In order to avoid the uncertainties due to human complement (17), 
this was first removed from the sera by admixture of triplicate 3 to 4.5 ml. portions with 1 
nil. of a  dilution of rabbit anti-egg albumin serum containing about 0.4 mg.  of antibody 
nitrogen and 1 ml. of a 0.9 per cent saline solution of crystalline egg albumin (Ea, containing 
about 0.04 rag. of Ea N).  This was found preferable to heat inactivation, which usually 
destroyed at least a portion of the antibody in sera of low content.  The Ea-anti-Ea precipi- 
tations were carried out at room temperature and allowed to stand until the precipitates 
flocculated (18), after which the tubes were left in the ice box for 48 hours and centrifuged 
in the cold. 
Aliquot portions of the supernatants were set up  as  follows,  in sterile, tapered,  Pyrex 
centrifuge tubes of about 7.5 ml. capacity :--Three portions were measured out, one serving 
as a blank.  To the other two, depending upon the intensity of a preliminary test with 1 ml. 
of serum, 0.005  '.o 0.02 mg. of pneumococcus C substance was added in a  volume of 0.1 or 
0.2 ml.  The contents of the tubes were thoroughly mixed with a  thin sterile glass rod or 
by rapid twirling.  After capping with sterile rubber caps the tubes were placed in a water- 
bath at 37°C. for one-half to one hour and were then allowed to stand 8 days in the ice box, 
with  occasional  twirling.  Precipitates often  formed overnight in  the  strongest sera,  but 
most of the weaker sera remained clear and required several days before the first small floc- 
cules separated.  When precipitates formed in 24 to 48 hours after addition of only 0.005 or 
0.01  mg.  of polysaccharide repeated analyses were often avoided by adding an additional 
0.01 rag.,  mixing as before, and allowing the tubes to  stand for 8  more days.  The tubes 
were finally centrifuged in the cold.  A second absorption with 0.005 to 0.01 mg. of C  sub- 
stance was usually carried out on the supernatants, especially when relatively large precipi- 
tates had formed.  The precipitates and blanks were washed in the cold in the usual way 
(3, 4) with chilled saline, stirring well, or twirling vigorously to ensure maximum disintegra- 
tion of the precipitate and thorough mixing.  When a  stirring rod was used, it was rinsed 
with  a  little chilled saline.  Supernatants from the washings were  often recentrifuged in 
order to recover any precipitate carried over, and usually the washings from duplicates were 
combined in larger centrifuge tubes.  A third washing was usually given all tubes.  Precipi- 
tates were dissolved in a few drops of 0.1 N sodium hydroxide, using a hand lens if necessary 
to make sure that the sometimes glassy precipitate was completely dissolved.  The solution 
of the traces of precipitate recovered on recentrifugation was divided approximately equally 
between the two duplicates.  The volumes were then made up with water to a calibration mark 
(usually 2.5 ml.) in the tubes, or the solutions were transferred to 5.0 or 10.0 ml. measuring 
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tions of dissolved precipitate were analyzed for nitrogen according to reference 5, with use of 
the Folin-Ciocalteau reagent and copper, and measurement of the blue color against that of 
the blank in a  Coleman spectrophotometer.  One hundredth to 0.04 rag.  (10 to 40 micro- 
grams) of antibody nitrogen in the aliquot proved most satisfactory, and in this range, suc- 
cessive determinations usually varied by only a  few thou-qandths of a  milligram.  The tyro- 
sine color value of the antibody was checked by direct comparison of the colorimetric with 
the micro-Kjeldahl method. 
The supernatant sera from the anti-C analyses, including the blank, were carefully drained 
into sterile centrifuge tubes, such as those suggested above.  To the duplicates from the anti- 
C  estimations were then added amounts of type-specific carbohydrate, depending upon the 
result of a  preliminary test with the supernatant of the 1 ml. of serum used in the previous 
preliminary test.  Usually, 0.005 to 0.05 rag. sufficed.  The analyses were carded out in the 
same manner as those for anti-C and supernatants were treated with more specific polysac- 
charide if the precipitates were relatively large.  In occasional sara precipitates formed al- 
most as quickly as in hyperimmune rabbit sera and analyses could be carried out by the 
micro-Kjeldahl method, or as described above with as little as  1 ml. of serum.  Analyses 
were carried out with S I  and S II successively, in either order, and in the sera of group 5, 
with S V, as well. 
Although this procedure is laborious and time-consuming it is accurate,' yields reprodu- 
cible values, and is well adapted to the analysis of large numbers of sera, as the work may be 
planned so that analyses on sets of four to six sara become due each day. 
In the earlier analyses S II was added after removal of the complement, and the analysis 
with S I  was run last.  In a number of instances, analyses were run in the reverse order as 
well.  Examples are given in the tables, and it will be noted that the order of analysis was 
immaterial.  After removal of  anfi-C  became routine,  the  order  of  analysis was  usually 
with C, S I, S II, and S V. 
Occasional sera, for reasons which are not yet apparent, required repeated absorptions 
with small quantities of C or S of one type or another for removal of all of the antibody in 
question.  A single addition of a  larger quantity of polysaccharide did not suffice. 
Numerous comparisons were made of heat inactivation and precipitation with Ea-anti-Ea 
for removal of the complement in the sera.  In all instances except that of  78, (Table III, 
footnote) heat inactivation resulted in marked reduction in the amount of precipitable anti- 
body, possibly because of more or less complete formation of non-precipitating complexes of 
antibody with albumin such as those noted on heating antisera to 75°C.  (19).  As most of 
these analyses were run before anti-C was estimated, only a later comparison, equally typi- 
cal, is given in the protocol. 
Pooled Serc~ of Various Bleedings 
Antibody estimated 
Anti-C ......................... 
Anti-I  ......................... 
Anti-II ........................ 
Micrograms antibody N  per 4 ml. 
Complement removed by 
Ea-anti-Ea 
Heal 56°i.,__  36 
8  10 
rain.  Heat, S6"C., 50 rain. 
0 
0 
0 
In another pool anti-C was reduced from 14 to 6 and 0, respectively; in a third, from 57 
to 30 and 22. 
4 Cf. comparisons with the micro-Kjeldahl method in Tables II and III.  Also, 85 to 95 
per cent of antibody added to normal serum was recovered analytically (unpublished ex- 
periments). TABLE I 
Comparison of A~gibody Levds in Human Beings after Intraculaneous Injections  of Typ~ 
I and II Pneumococci or Their Specific Polysaccharides 
Micrograms antibody N per 4 ml. serum 
Subject  Anti-  Bleeding No. 
No.  bodies 
tl  ' 
to  0*  1  2  3  4  5  6  7  8  3 to 4 
Before  3wks.t  6wks.  3mos.  Smos.  6mos.~  12mos.§  14mos.]  2yrs.**  mos. 
later 
C  23  29 
I  0  1  0  1  2  1  338442  2  0  II  0  +  +  7  7  8  3  5  3  7 
15  C  28  14  20 
I  0  82  91  64  61  60  30  33 
II  0  39  56  44  41  34  [  25  I  21  11  18 
I  I 
19  C  [  16  29  29 
I  0  29  24  24  25  22  15  [  8  4  11 
II  0  142  144  118  100  88  [~57~ I  57  43  49 
121  3 to 4 
$mos.t  10| mos.§  mos.A  23mos**  mos. 
later 
Group 1 
8 
2J  mos.  4mos. 
Group 2 
32 
29 
31 
C 
I 
II 
C 
I 
II 
C 
I 
II 
47  57  52 
0  0  4  6  3  1  4  3 
6  3  3  3  7  3  1  5 
24  44  37 
36  40  31  30  27  14  13  11 
22  27  21  25  25  18  ~14  21 
26  70  62 
29  19  7  12  30~  4  8  5 
51  43  33  30  9~  7  6  13 
Initial values for group 1 in part by micro-Kjeldahl method; data for first 4 bleedings of 
sera 8, 32 probably too low, owing to use of too much S I and S IL  No anti-II was found 
in 321 after heat inactivation.  In 1510, 2 years after last analysis above, anti-I, 17. 
* Before vaccination. 
t After second injection. 
2~ to 4 weeks after skin-testing with 0.01 rag. each S I  and S II.  Positive tests were 
irregular. 
§ Followed by reinjection, subcutaneously, of 0.025 to 0.05 rag. each S I and S II. 
[[ Two months after reinjeetion. 
** 10 months after reinjeetion.  Again injected subeutaaeously with 0.04 rag.  of each 
polysaccharide. 
tt Values out of line, reason unknown. 
:~ Original value 33.  Repeated after 2.5 years,  ~.57. Two  absorptions  were carried 
out; a third was indicated. 
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As shown by comparative analyses on 78~, with and without 0.5 per cent phenol, this 
preservative can be used even though the final nitrogen estimations are made with the Folin- 
TABLE II 
Comparison of Antibody  Levels gn Human Beings after Subcutaneous or Intracutaneous Injec- 
tions of Specific Polysacckarides of Types I and II Pneumoco¢¢us 
Subject Na 
Group 3 
42 
43 
38 
Group 4 
51 
56 
53 
6 
I to 5 mo$. 
later 
21 
3 
6 
37 
10 
155 
* Followed by reinjection, subcutaneously, of 0.025 rag. each S I and S II. 
t  FoUowed by subcutaneous reinjection of 0.04 rag. each S I and S II. 
Repetition gave anti-C, 44; anti-I, 13; anti-II, 54; anti-VII, 11. 
§ By micro-Kjeldahi. 
U  Colorimetric analysis 1.5 years later gave anti-C 20; anti-I, 104; anti-II, 13. 
** A sample from which complement was removed by heat inactivation instead of by 
Ea-anti-Ea gave anti-C, 18; anti-I, 5; anti-II, 187. 
tt Anti-II N for bleedings 1, 2, and 3 by micro-Kjeldahl, 268, 305, and 244 respectively. 
After 1.5 years a colorimetric analysis of bleeding 3 showed anti-C, 23; anti-I, 7; anti-II, 199. 
:~ Anti-VII in bleedings 3, 4, and 5: 2, 11, and 2, respectively. 
Ciocalteau phenol reagent.  The washings recommended suffice for quantitative removal of 
phenol as well as of non-specific proteins.  This applies equally to merthiolate,  z which also 
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TABLE  III 
Antobody Levels in Human Beings after Subcutaneous Injections of Specific Polysaccharldes of 
Types I, II, and V Pneumococcus 
Micrograms antibody N per 4 ml. serum 
Subject  Bleeding No. 
No. 
61 
O*  I  2  3  4  5  6 
Before  2 wks.t  6 wks.  5t mos.~  8 mos.  15t mos.~  4-5 mos.  later 
49  45  63  77 
0  0  1  1  I0  0  2 
0  0  0  11  1  1  0 
0  0  0  8  2 
62  9  7  12 
0  54§  (56)  50  19  18 
0  81  79  45  25  23 
0  10  10  7 
63  18  18  29 
0  25  26  12  6  3 
0  1?  24  9  6  6 
1  24  24  5 
64  32  26 
4  67  122  104  93 
1  33  53  21  22 
0  45  56  47  40 
65  11  12  20 
0  16  15  8  17  9 
0  33  49  38  38  27 
1  11  16  4  3 
67 
68 
47  64  53  69 
0  18  27  20  15  11  9 
0  67  82  62  50  31  35 
1  24  39  22  22  10 
25  17  19 
0  33  32  15  31  15 
0  (16)  14  3  6  8 
1  (28)  18  3  2 
* Pool containing 0.75 ml. each 62-82: anti-C, 23; anti-VII, 9. 
t  After second of injections 3  days apart. 
Followed by reinjection of 0.05 rag. each S I and S II (after bleeding 3, except Nos. 65, 
68, 75, and 76).  Reinjection after bleeding 5: same  amounts, except that No. 80 received 
0.05 mg. S V in addition. 
§ After 5 months, repetition on a  smaller sample gave: anti-C, 5; anti-I, 49; anti-II, 63; 
anti-V, 6. TABLE  III--Continued 
Micrograms antibody N per 4 ml. serum 
Anti-  Bleeding No.  Subject 
No.  bodies  to 
0*  1  [  2  3  "  4  5  6 
Before  2 wks.t  [  6 wks.  5[ mos.S  8 mos.  15~ moss  4-$ mos.  later 
69 
7O 
71 
72 
73 
74 
75 
76 
78 
C  9  12  22  ~  27 
0  30  32  19  20  10115  I 
II  1  41  46  32  31  19  I  25 
V  0  6  13  2  0  I 
C  37  43  54  i  67 
I  0  22  25  14  12  13  14 
II  0  36  34  24  26  31 ?  28 
V  0  14  24  7  3  ! 
C  13  15 
I  0  29  36  20  43 
II  5  39  34  38  36 
V  1  30  36  10  8 
C  15  24  38  57 
I  1  18  17  7  13  4  ,  5 
II  0  3  18  27  36  21  i  22 
V  0  11  31  (8)  4 
I  0  39  46 
II  0  72  74 
V  1  12  15 
C  50  41  70  67 
I  1  18  23  12  27  9  9 
II  2  64  (83)  88  76  48  53 
V  0  15  23  Ii  8 
C  47  63  44"  45 
I  2  12  17  14  33  11  10 
II  5  12  14  3  9  15  (13) 
V  2  12  15  7  8 
C  97  109 
I  !  3  135  196  156  76 
II  0  59  71  43  29 
V  1  34  39  9 
c  18  18U  37  31 
I  2  69  74  58  46  41  41 
II  2  35  42  34  25  20  20 
V  0  49  60  37  33  20  5 
In order C,  I, II, V.  Order C, V, II, I  gave 19,  45, 22, and 51,  respectively.  This 
serum, contrary to most others, showed no marked change in either order after removal of 
complement by heat  inactivation  instead  of  by Ea-anti-Ea. 
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TABLE III--Conduded 
Micrograms  antibody N per 4 ml. serum 
Subject  Bleeding No. 
DO~Ue$  to 
O*  1  1  3  4  ]  5 
Before  2 wks.t  6 wks.  5t mos.t  $ mos.  IS| mos.t 
C  43  75  69 
I  0  7  7  14  9  2 
II  0  14  28  29  26  19 
V  1  28  36  35  30  19 
a 
~.$ mos. 
hirer 
73 
4 
>19 
C  12  25  32  34 
I  6  72  63  73  54  45  39 
n  1  37**  18  12  11  10 
V  1  129  136  166  143tt  97  1<113 
i 
C  '  17  15  26  i  24 
I  1  15  21  17  i4  10  ~  10 
II  1  23  29  12  12  10  i 
V  0  1  2  5  1 
C  74  41  63  68 
I  3  14  16  7  l0  4  3 
II  1  57  78  50  44  24  24 
V  1  74  79  57  51  24 
** In order II, V, I.  Order  V, n  gave anti-V, 139; anti-II, 31. 
tt By micro-Kjddahh 146. 
A nalytical Data 
Group I: In Table I are given values for antibody nitrogen in 4 ml. of  serum 
of volunteer 8,  the  poorest antibody former in  the  group,  No.  15,  the best 
producer of antibody to Type I, and No. 19, the best for Type II.  Averages 
for the group are to be found in Table IV. 
Group  2: Data  on  three  subjects,  corresponding  to  those  selected  from 
group I, are also given in Table I.  Averages in Table IV. 
Groups 3  and  4:  Data  on  the  poorest  antibody former in  the group and 
the best for each type are given in Table II.  Averages in Table IV. 
Group 5: Since the analyses on the sera of this group were carried out after 
the second bleeding with removal of anti-C before measurement of the type- 
specific antibody response,  it is  believed  that  the data reflect with  some ac- 
curacy the wide variety of the response of human beings to simultaneous im- 
munization  with  several  polysaccharides.  They are  therefore  given  in  full 
in Table III.  Averages in Table IV. TABLE IV 
Mean Values of A~ibody N~rog~ 
Micrograms antibody  N  per 4 ml. serum 
Bleeding No.  Subjects 
to 
1  2  3  4  5  6  7  8  9 
3 wks.  6  wks.  3 mos.  $ mos.  6  mos.*  12  mos.  14  mos.  2  yrs $  3  mo$.  later 
Group I 
C 
I 
II 
25  38  46 
26  31  24  21  22  19  10  9  13 
56  55  44  40  35  27  20  19  2211 
26-27  3wks.  2~mos.  4mos.  5mos.* 101mos  12|mos.t  23mos.  mos.§ 
Group 2 
C 
I 
II 
Group 3 
C  2 
I 
II 
Group 4 
C 
I 
II 
40  64  76 
13  13  9  10  14  4  6  6 
20  22  19  18  18  10  7  13 
3--4wks. 2§mos.  8mos.  t0mos.  ~  20-23  mos. 
27  40t~ 
is  18  17  8  6H 
37  45  44  33  18~ 
20-23  1-5 mos. 
3-1wks.  2½mos.  8mos.  lOmos.t  mos.~$  late~ 
Group 5 
C  I  231[111 
II  1 
V  1 
28  2511  24tt 
27  35  34  20  8}l  11tt 
58  69  58  50  43U  47tt 
s½  ls~  2  wks.  6  wks.  mos.§§  8  mos.  rnos.~§ 20-21  mos. 
35  31  44  49*** 
33  29  33  29  17  13"** 
31  28  31  29  20  21t~f 
25  22  26  22 
* 2,5 to 4 weeks after skin tests with 0.01  rag. S I  and S II. 
t  2 months after reinjection with S I and S II. 
;~ 8 subjects, reinjected alter bleeding. 
§ 3 to 4 months after second reinjection, 6 subjects. 
]l 5 subjects. 
** Separate  analysis  on  several  pooled sera. 
~t  4 subjects. 
:~  Followed by second reinjection. 
§§  Followed by reinjection  with  S I  and S II  only. 
][I[  Separate  analysis  on  pool  of  all  sera;  subsequent analysis  for  anti-VIii  9/~g. 
*** 14 subjects. 
~t  13 subjects. 
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DISCUSSION 
Quantitative analyses have already been presented on the antibody content 
of ~he sera  of patients shortly after recovery from pneumococcal pneumonia 
(6).  The present data on the human response to vaccination with pneumo- 
cocci or their type-specific polysaccharides  were obtained concurrently, and, 
in their larger subject material and longer period  of observation,  supplement 
and extend the still all too small  body (6,  15, 20) of analytically exact data 
on the immune response of human beings. 
Perhaps  the most  surprising  result  of the  investigation, although an  in- 
herently reasonable  one, was the constant finding of antibody to the C sub- 
stance of pneumococcus in normal and immunized subjects,  as already noted 
(6).  In general, the prevaccination bleedings contained little or no antibodies 
to the specific polysaccharides of Types I, II, III, and V pneumococci.  When, 
however,  Type VII polysaccharide  was added, most of the sera  gave appre- 
ciable  precipitates and  it  was  found that  the reaction was  usually due,  in 
large measure,  to the high C content of the preparation of Type VII polysac- 
charide used.  Analyses with C isolated from other types and from pneumo- 
cocci in the Dawson S phase showed that the C-anti-C  reaction behaved as 
a true antigen-antibody interaction in that the serum component occurred  in 
the globulin fraction (6).  It was therefore unlike that observed in the sera of 
patients in the acute febrile phase of numerous diseases, in which  C  reacts 
with an albumin-like protein  temporarily present (8a, 21).  Another remark- 
able feature of the C-anti-C reaction was the comparative constancy, for any 
one subject, of the values of anti-C over periods  as long as a year or more. 
This is shown in the values for anti-C given in the tables; indeed, certain of 
the volunteers might actually have been identified  solely by the anti-C con- 
tent of their sera.  Such variations as may be noted are doubtless due in part 
to the greater uncertainty of the earlier analytical estimations,  and in part to 
the unfortunate use, in some of the analyses,  of C derived  from formalinized 
cultures.  Such preparations appeared to give higher results  than the others, 
possibly owing to condensation  of C molecules into a formaldehyde-C polymer 
Capable of co-precipitating  other globulins with the true antibody.  Possibly, 
also,  the  preparations  varied  with  respect  to  their  content of  undegraded 
Forssman antigen (8d, e).  The results  did not appear  to  be  influenced  by 
blood group A substance, which contaminated some of the C preparations (see 
experimental part). 
A possible explanation of the apparent state of equilibrium existing in most 
of the subjects with respect  to the C antigen may lie in the more or less con- 
stant occurrence of pneumococci in one phase or another in the nose and throat 
(22).  Human beings would then be under a continuing stimulus due to this 
somatic antigen common  to all pneumococci,  and each  person  would  react 
characteristically and with the individual variability noted  in other animals 
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Up to the time anti-C was removed  before estimation of the type-specific 
response,  all of the preliminary, or 0 bleedings, had been analyzed and many 
of the subsequent  ones as well.  All of these postvaccination values, therefore, 
are probably too high by variable amounts diificult to evaluate, but depending 
upon the often appreciable  quantity of C  substance in the sample  of type- 
specific polysaccharide  used.  The magnitude of these errors was indicated in 
some instances,  recorded in the tables,  by later analyses in which the anfi-C 
was first removed, but it is by no means certain that the full difference recorded 
was always due to the prior removal of the anti-C, since the sera, although kept 
sterile and in the cold, might have deteriorated during storage.  The question 
also arises why so many of the sera  in the 0 bleedings gave no precipitates 
with S I and S II in spite of their often high anti-C content and the presence 
of traces of C in the specific polysaccharides.  It is likely that the traces of 
C substance present in these analyses would give rise to precipitates only in 
exceptional normal sera, whereas in the sera after immunization, small amounts 
of C-anti-C  complexes, which might not separate by themselves, would prob- 
ably co-precipitate  with the insoluble S-anti-S formed. 
The features of the type-specific antibody response can be outlined by first 
considering the data for each group of subjects. 
Group 1: Two s.~parate intracutaneous injections were given,  totalling 10 
billion each of pneumococcus Type I and Type II containing 0.03 rag. of SI 
and 0.04 mg. of S II.  In Table I are given the antibody contents of the sera 
of various bleedings of selected subjects in micrograms per 4 ml. of serum, 4 
ml.  being  the  average quantity used for each  blank  and determination in 
duplicate.  Data are given for subject 8, the poorest reactor in the group,  15, 
the best producer of antibodies to the specific polysaccharide of Type I pneu- 
mococcus (anti-S I), and 19, the highest in anti-S II.  It will be noted that 
the antibody content of the sera reached  the maximum within 3 to 6 weeks, 
and remained almost constant for about 5 months, in general agreement with 
others (1, 2).  The behavior of the sera of the other members of the group was 
similar. 5  After 5 months the subjects were given intracutaneous skin tests of 
0.01 rag. S I on one arm and 0.01 rag. of S II on the other, but the intensity of 
the immediate and 24 hour reactions bore no relation to antibody levels in the 
sera, in agreementwith references 1 e, 2 a.  It might have been expected (1) that 
these tests would have acted as booster doses and increased the antibody level, 
but the next bleeding, No. 5, 2~ to 4 weeks later, showed no such effect, nor 
was there an increase in the average values for the entire group (Table  IV). 
At the end of another 6 months, one year after the original injections, the anti- 
t Full data on the sera of the intermediate members of groups 1  to 4 are on file in a  final 
report to the Pneumonia Commission, Army Epidemiological Board~ but are omitted here 
in order to conserve space, as it is believed that the figures for group 5, given in full, are more 
accurate and  lead  to  the same conclusions.  Copies of  the data  for groups 1 to 4  will  be 
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body levels had dropped to two-thirds to one-half of their original values.  At 
this time the students were reinjected subcutaneously with 0.025  to 0.05  rag. 
of S I and S II, and again there was no increase in the antibody content of the 
sera.  Instead, the slow decrease continued.  At the end of the second year a 
few subjects were reinjected a second time, but only a very slight rise in anti- 
body content occurred. 
Group  2:  In  order  to  make  the  conditions of  a  comparison of  polysac- 
charide with intact pneumococci as close as possible, an attempt was made to 
inject the polysaccharides in particulate form in the same quantities as in the 
bacterial vaccines.  The  insoluble  copper  salts  were  used  for  this  purpose, 
but as the precipitates were gummy and tended to stick in the syringes, most 
of these subjects probably received less than 0.03 rag. of  S I  and 0.04 rag. of 
S II.  Possibly for this reason the average antibody formation was less  than 
in group 1 (Tables I  and IV).  Results of skin-testing and reinjection were, 
on the whole, negative, as in group 1. 
Groups 3 and  4  (Table  II): In group 3,  0.05  rag.  each  of S I  and S II 
in solution in phenolized saline was injected intracutaneously, while in group 
4  the same  amounts were  injected  subcutaneously.  Antibody values  were 
somewhat higher in group 4  than in group 3, but the difference was scarcely 
greater  than might be  expected  between  two small groups.  Subcutaneous 
injection of the polysaccharides is, however, certainly no less effective than by 
the intracutaneous route, as indicated also in references 1 and 2.  These groups 
averaged about the same antibody content as group 1, although several indi- 
viduals  showed  much  greater  antibody  formation.  While  slightly  more 
polysaccharide  was  given  groups  3  and  4,  complaints  due  to  reactions 
were fewer, perhaps because the bacterial proteins injected into group  I  were 
not  present  in  the  polysaccharide mixture.  In  these  groups  the  antibody 
levels persisted almost unchanged for 8 months (Tables II and IV)  and were 
not increased on reinjection.  There was considerable individual variation in 
the rate of decrease after this period, but between one-tenth and  one-half of 
the maximum antibody content was still circulating after 2 years. 
Group 5:  This  groupp  the largest, was  injected  subcutaneously with 0.06 
rag. each of S I, S II, and S V.  Commercial products, made by the phenol 
method (13),  were used.  s  The data on the various bleedings are given in full 
in Table III.  Beginning with bleeding 3, estimations of anti-C were carried 
out before the sera were analyzed for type-specific antibodies, and the trends 
of the antibody response to four different carbohydrate antigens can therefore 
be followed in detail.  It will be noted that the anti-C content of most of the 
sera remained relatively constant.  It is also evident that a vigorous response 
to one type-specific antigen by no means indicated a  like response to one or 
both of the remaining two (of.  also 1, 2), and that all possible combinations 
6  Manufactured by  K. R. Squibb  & Sons  for  use  by the  Pneumonia Commission. ~15  ANTIBODY  ~OR~ATION  TO  PNEUMOCOCCI AND  POLYSACCHA~DES 
of selective behavior were  represented.  It  is apparent  also,  in  conjunction 
with the figures in the other tables, that ability to form antibody to any one 
type was not correlated with ability to form antibody to the somatic C antigen 
of pneumococcus.  While  in groups 1 to 4  S  II appeared  to  function as a 
better antigen in general than S I, the average antibody response to both was 
about  the same in group 5.  Except  in a  few students, antibody to S V was 
far lower in quantity than was anti-I and anti-II, but in one of the exceptions 
the value was the highest for any antibody in  the group; consequently the 
average value for anti-V differs little from that for anti-I and anti-II.  On 
account of the great individual variability shown, therefore, the average values 
given in Table IV are of service only in emphasizing the slow tapering off of 
the antibody levels and the failure of booster doses to produce the anticipated 
effect. 
It isdiffcult to assign a  reason for the failure Of reinjections of the polysac- 
charides to produce a  secondary rise in antibodies even when the antibody 
level had fallen, after 2 years, to a fraction of its original value.  The specific 
polysaccharides of pneumococcus are, however, resistant to the usual carbo- 
hydrate-splitting enzymes (24).  It is therefore possible that S I, S II, and S 
V enter into long lasting combination with some cellular constituent, and that 
this combination provides the observed antigenic stimulus over  the compara- 
tively long periods of observation to which the groups of students were sub- 
jected.  If, at any period, the body should make its maximum response to the 
residual antigen available,  injection of a  further small quantity would not 
necessarily increase an already maximal effort at the production of antibody, 
even though the current level were below the original.  One would not then 
expect reinjections of polysaccharide to exert much effect until all residues of 
previous  injections had  disappeared,  and  this  state  would  be  indicated  by 
disappearance  of  the  antibody.  It  is  hoped  to  test  this  possibility,  which 
would  scarcely apply  to  protein  antigens,  as  these  are  probably  relatively 
rapidly degraded by the proteolytic enzymes of the body. 
While it has long been known from studies with mice (25) and men (1,  2) 
that extremely minute quantities of the specific  polysaccharides of pneumo- 
coccus are capable of eliciting an antibody response in the sera of these ani- 
mals, the extreme variability of the data and their relative nature precluded 
any realization of the actual quantities of antibody circulating at the time of 
testing.  The data now presented  in  the  tables  show that, in favorable in- 
stances,  this response may be  enormous when compared with the few hun- 
dredths of a  milligram of polysaccharide injected.  For instance,  it  can be 
calculated, with the use of an average human blood volume of 7 liters, that 
subject 53 produced within 3 weeks more than 25,000 times as much circulating 
anti-S  II  ~ as  the amount of polysaccharide injected.  This result surpasses, 
T  217 mg. antibody N X 6.3 =  1370 rag. antibody protein in 3.5 liters of serum. HEIDELBERGER~  MAcLEOD,  KAISER,  AND ROBINSON  317 
relatively,  the  antitoxin-producing capacity of  a  horse  s  calculated  to  have 
elaborated more than  10,000  times as much circulating antibody as  the  60 
rag. of diphtheria toxoid injected over a  period of 1 month (26).  When one 
considers that the average half-life of an  antibody molecule  (in  the  rabbit) 
has been calculated to be about 2 weeks (27), s while the antibody level in sub- 
ject 53 remained constant for 8 months, the relative enormity of the quantity 
liberated into the blood stream becomes even more striking.  This is, of course, 
the extreme case, but there were several other subjects whose response to S I, 
S II, or S V was roughly equal in relative magnitude to that of the horse in 
question, while the majority of subjects fell far below this level.  The data 
suffice to show, however, that in man the specific polysaccharides of pneumo- 
coccus are among the most powerful antigens known. 
Although no evidence of a  secondary rise in antibody levels was obtained 
following the reinjection of specific  polysaccharides, the possibility was con- 
sidered that subjects showing exceptionally high antibody production to one 
or another of the potysaccharides might have had previous experiences with 
pneumococci of the type in question.  In several  such instances questioning 
elicited no evidence of previous infections that might have been responsible. 
Nos. 53 and 54, both good producers of anti-S II, had had lobar pneumonia 
several years earlier, but correspondence with their physicians showed that the 
offending pneumococci had been of Types VII and I, respectively. 
As noted in the tables and in references le and 6 many of the sera contained 
appreciable antibody to S VII, even after removal of the anti-C.  This is the 
only one of the  type-specific polysaccharides so  far tested  to  give frequent 
reactions in the sera of normal individuals.  Whether or not this is indicative 
of a  cross-reaction with other antibodies is not yet clear. 
It remains to consider the quality of the antibody formed and whether or 
not the quantities found in the serum would, in general, be sufficient to pro- 
tect human beings against infection by pneumococci of the types of which the 
specific polysaccharides were injected.  Evidence on the first of these points 
is presented in the accompanying paper (7) and in another yet to appear (23), 
from which it is apparent that antibodies elicited by small injections of pneu- 
mococci or their type-specific polysaccharides are not usually equal in protec- 
tive power to antibodies from hyperimmunized animals. 
8 The experiment of Knorr  (Mil,  ch meA. Wodt.,  1898,  45,  321, 362)  frequently cited as 
the maximum recorded antibody rise (100,000 units per toxin unit injected), is not strictly 
comparable since it reflected an increase due to  booster doses, not the primary injections. 
Even so, Knorr's result is of the same order of magnitude as those under discussion, as the 
figure should be 50,000 units per toxin unit injected, not 100,000,  as given by Knorr, since 
the units were measured in the serum, not in whole blood, the volume of which was used for 
the calculation. 
"Half-life" is here understood to indicate the balance between formation and destruc- 
tion.  The rate of disappearance of serum globulin  in man is similar (personal communica- 
tion, Dr. David Rittenberg and Dr. David Shemin). ~I~  ANTIBODY FORMATION  TO PNEUMOCOCCI  AND  POLYSACCIIA~RIDES 
With  regard  to  the protective value of the immunization procedure,  the 
evidence that pneumonia patients may show circulating type-specific antibod- 
ies at the outset of the disease (28) would appear at first sight to argue against 
the protective power of such antibodies.  However, it has been pointed out 
(28) that the pneumococcidal test employed is 10 to 100 times as sensitive an 
indicator of antibody as the mouse protection test, which is usually negative 
under the same circumstances.  The amounts of antibody circulating in the 
patients studied in reference 28  must therefore have been of a  much lower 
order of magnitude than the precipitating and mouse-protecting (7) antibodies 
elaborated  after injection of the polysaccharides.  Evidence on the positive 
side was obtained from a study of serum therapy of pneumococcal pneumonia 
in rats (29).  A  sample of the rabbit serum concentrate used contained 7.13 
rag.  of anti-S  I  N  per ml.,  1° and 0.02  ml., injected intravenously into rats, 
regularly terminated 12 hour pneumonia due to Type I  pneumococci, while 
0.002  ml. did not.  It was calculated that the 140 micrograms of antibody N 
(or less) having the curative effect would be diluted to about 10 micrograms (or 
less) per ml. of blood, or 80 micrograms (or less) per 4 ml. of serum in the aver- 
age rat.  Although this is only roughly double the average antibody response 
to the polysaccharide injections in man, the injected antibody sufficed to cure 
an already established infection, so that presumably less antibody would be 
required  merely to  protect.  Also,  infinitesimal amounts of  antibody must 
have sufficed to protect mice in the tests employed in references 1 and 2, since 
values up to 10  X  10  6 protective units were obtained in sera which were ob- 
viously weak as compared with those from hyperimmunized animals.  Since, 
in addition, active immunity should be more effective and lasting than passive 
immunity, it was concluded that further tests of the immunization of human 
beings against pneumonia were warranted.  The results of a  field test  (16) 
appear to have justified this conclusion. 
SUMMARY 
1.  A  modification of  the  microanalytical quantitative precipitin  method, 
five to ten times as sensitive as the older procedure, has been used to measure 
the  type-sPecific  antibody response  in  human  beings.  Injections  of  type- 
specific  pneumococci  or  equivalent  amounts  of  their  type-specific  poly- 
saccharides  led  to  comparable  antibody  production.  In  general, the  few 
hundredths of  a  milligram of  polysaccharides injected  functioned as extra- 
ordinarily powerful antigens. 
2.  Subcutaneous injections of the polysaccharides were as effective as in= 
tracutaneous, and the resulting antibody levels, which were highly variable 
individually, remained relatively constant for 5 to 8 months, gradually taper- 
10 A  sample of the serum was kindly supplied by Dr. E. N. Irons and analyzed in this 
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ing off  during periods of observation that exceeded 2 years in some instances. 
3.  After the injection of several type-specific polysaccharides widely diverse 
combinations of selective and non-selective responses were observed. 
4.  Booster doses had  little  or no effect in increasing  circulating  antibody, 
even after 2 years.  A tentative explanation is given of this unexpected result. 
5.  Possibly because they frequently harbor pneumococci, normal human  be- 
ings appear  to be in  serological equilibrium  with  the  C-antigen  of pneumo- 
coccus, since in most instances  the quite appreciable  anti-C  content of their 
sera remained  relatively constant  during periods of a  year or  longer.  Many 
of the sere also contained antibody to S VII. 
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